AbCellera Biologics Inc.
ABCL
$4.18
-$0.12-2.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.07% | -14.28% | -11.24% | -36.13% | -107.42% |
| Total Depreciation and Amortization | -44.78% | 112.30% | 110.39% | 220.78% | 118.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 78.03% | -80.16% | -74.07% | -95.84% | -60.04% |
| Change in Net Operating Assets | 110.72% | 26.67% | -295.41% | -196.39% | 81.35% |
| Cash from Operations | 11.54% | -88.82% | -147.41% | -1,908.11% | 23.86% |
| Capital Expenditure | 26.41% | 24.63% | -1.88% | -3.14% | -17.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -40.54% | 269.16% | 238.60% | 199.70% | 129.78% |
| Cash from Investing | -65.42% | 339.09% | 154.91% | 128.70% | 109.29% |
| Total Debt Issued | 18.43% | 23.12% | 28.14% | 102.37% | 2,906.90% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -11.33% | -61.53% | -78.98% | -78.98% | -68.93% |
| Repurchase of Common Stock | -46.30% | -46.30% | -46.30% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,174.56% | -53.29% | 40.92% | 29.74% | 33.60% |
| Cash from Financing | -37.76% | 16.58% | 23.30% | 78.56% | 5,356.01% |
| Foreign Exchange rate Adjustments | 46.03% | -6,033.33% | -544.31% | 631.30% | 89.23% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -77.75% | 151.40% | 109.06% | 77.15% | 94.85% |